drugset / Trial / NCT00507728

Pharmacogenetics, Emotional Reactivity and Smoking

NCT00507728

RandomizedParallel-groupDouble-blindTreatment

Summary

The goals of this placebo-controlled randomized clinical trial were to evaluate the differences in emotional reactivity (peak startle response to affective stimuli) during a cessation attempt among smokers treated with bupropion, varenicline, or placebo, and to determine if these differences were moderated by genotype.

Timeline

Start
2005-12-08
Primary completion
2019-12-18
Completion
2019-12-18

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bupropion Small molecule 150 mg Oral
Subject Varenicline Small molecule 1 mg Oral

Indications